RxDoctor Payments Data

Ceara Steiner, OD

Optometrist · Billings, MTNPI 1174858732

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.6% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Alcon at 47.0% of the total.

$1,046in general payments, 2019–2025

Across 31 payments — averaging $33.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$491
  • Glaukos Corporation$210
  • Rxsight Inc$141
  • Dompe US, Inc.$40
  • AbbVie$39
  • Bausch & Lomb Americas Inc.$36
  • plus $89 from 5 others

What the payments were for

  • Speaking & faculty fees$262%
  • Food & beverage$1,02198%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,046 in reported general payments places this provider in the 80th percentile of 184 optometrist providers in Montana.

See all optometrist providers in Montana

Medicare billing

Part B allowed, 2024
$187,049
Medicare patients
911
Services billed
1,797

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate32$13,974
LumiganBimatoprost22$9,740
RocklatanNetarsudil Mesylat/Latanoprost20$7,016
Prednisolone Acetate135$6,103
IlevroNepafenac13$5,213
Latanoprost382$2,426
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat122$2,402
MoxifloxacinMoxifloxacin Hcl80$2,174
Brimonidine Tartrate74$1,600
Fluorometholone14$1,016
Ketorolac Tromethamine23$830
Timolol Maleate85$636
ValacyclovirValacyclovir Hcl11$407
ErythromycinErythromycin Base17$174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$39$9,74022 claims
NovartisIlevro$16$5,21313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 184 optometrist providers in Montana.

Other optometrist in Billings

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →